Compliance Group Inc. and Loftware Announce Strategic Partnership to Drive Digital Labeling Transformation in Life Sciences
Purpose-Driven Partnership for a Compliant, Scalable Future
Loftware's powerful, cloud-enabled labeling technology with CG's deep labeling expertise and proven Computer Software Assurance (CSA) aligned validation strategies, the partnership delivers:
World class labeling consulting & End-to-end support
Insights into inefficiencies and compliance gaps in legacy systems
Expert guidance on system migration & architecture alignment
FDA, MDR, Global ISO compliant validation (IQ, OQ, PQ)
Integration with enterprise systems (SAP, Oracle, Veeva, etc.)
Real-World Impact: Leading Global MedTech Transformation
A global leader in medical devices selected CG to lead the replacement of their Global Labeling System (GLS). Our team conducted:
Thorough assessment of legacy system
Vendor selection & Loftware readiness planning
Define requirements with expert consulting
Validation aligned with CSA, FDA, & Global ISO standards
Full implementation with audit readiness
Executive Perspectives
"Our partnership with Loftware reinforces our commitment to helping clients build innovative, scalable, and compliant labeling systems. With our AI powered design validation approach, we enable life sciences companies to move faster while staying inspection ready.' added Sarat Bhamidipati, CEO, Compliance Group Inc.
"We're excited to partner with Compliance Group to help life sciences organizations modernize their labeling environments while meeting the industry's rigorous regulatory requirements. By combining our cloud-based labeling solutions with Compliance Group's deep validation and regulatory expertise, we're enabling companies to accelerate digital transformation, reduce risk, and ensure long-term compliance," added Carter Johnson, Vice President, Global Alliance Sales at Loftware.
About Compliance Group Inc.
CG is a leading consulting & validation partner for the Life sciences industry. Our experts bring decades of regulatory experience & specialize in validation, label consulting, and digital transformation. With a vendor-neutral, AI-driven approach, we use people, platforms, and processes to build a compliant, scalable quality system. Learn more at www.complianceg.com
About Loftware
Loftware is the global leader in product identification, artwork management, and connected packaging. Our cloud-based solutions power real-time collaboration, ensure compliance, improve authenticity, and deliver supply chain visibility from product development to consumer engagement. We provide scalable, data-driven labeling and packaging technologies that help companies boost speed to market, enhance efficiency, and connect physical products to digital experiences. Trusted by global brands and backed by over 40 years of innovation, Loftware supports customers across industries with offices in the US, UK, Slovenia, China, and Singapore. Learn more at www.loftware.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions, today announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia. "This IND clearance represents a major milestone for EuMentis as we advance EM–221 through Phase 2 clinical development," said Frank Stonebanks, Chief Executive Officer of EuMentis. "EM–221 is more than a single asset—it represents a pipeline in a product with potential applications across multiple neuropsychiatric and neurodevelopmental conditions. As we enter this next phase, we're excited by the opportunity to unlock significant therapeutic and commercial value in schizophrenia and beyond, supported by a world-class team and leading scientific collaborators." EM-221 is targeting PDE10A, a key intracellular enzyme that regulates dopamine and glutamate signaling in brain regions implicated in schizophrenia. Unlike traditional antipsychotics that broadly block dopamine receptors and are associated with serious side effects such as weight gain, movement disorders, and sedation, PDE10A inhibition offers a more targeted mechanism that modulates these pathways without direct receptor antagonism. "We are very excited to receive IND clearance from the FDA for schizophrenia, which is a serious, lifelong disorder affecting nearly 4 million adults and adolescents in the U.S. alone," said Dr. Randall Marshall, Chief Medical Officer of EuMentis. "There is a wealth of data suggesting that a PDE10A inhibitor can benefit individuals with schizophrenia as a more effective, safer, and better-tolerated therapy. We look forward to initiating our Phase 2 study of EM-221 later this year." EM–221 is a next-generation, selective PDE10A inhibitor designed to maximize efficacy while minimizing off-target effects. Preclinical and phase 1 clinical studies suggest EM–221 may offer superior tolerability and a broader therapeutic window, positioning it as a potential best-in-class treatment for both the positive and negative symptoms of schizophrenia—a critical gap left unaddressed by current therapies. "Despite decades of use, current dopamine receptor-blocking antipsychotic medications remain limited in their tolerability and effectiveness which make them unacceptable to many patients," said Dr. John Krystal, Robert L. McNeil, Jr. Professor of Translational Research and Chair of Psychiatry at Yale School of Medicine. "The PDE10A mechanism represents an important and innovative approach to modulating dopaminergic and glutamatergic signaling in the brain. I'm encouraged by the potential of EM–221 to offer a new therapeutic option for patients who urgently need safer and more effective treatments." About EM-221 EuMentis is building a pipeline-in-a-product around EM-221. EM-221 is an innovative product that targets the phosphodiesterase 10A enzyme, uniquely concentrated in the brain's striatum, to enhance cyclic nucleotide signaling and balance dopamine pathways. Unlike traditional antipsychotics, it offers the potential to address not only the positive symptoms like hallucinations but also the challenging negative symptoms—such as social withdrawal, blunted emotions and difficulty planning—that often persist untreated. EM-221 has been cleared by the U.S. FDA for Phase 2 evaluation, and the company expects to begin dosing in its first clinical trial in the second half of 2025. About EuMentis Therapeutics EuMentis is a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central nervous system (CNS) conditions. EuMentis is committed to leading innovation in the neuropsychiatric disease field by advancing programs that target selective CNS circuits in the brain with clinically validated mechanisms of action. This approach will enable its therapies to achieve better efficacy and tolerability, with the goal to deliver improved outcomes for patients. The Company's lead product, EM-221, is a potentially groundbreaking advancement in schizophrenia treatment, with a new, differentiated PDE10A inhibitor. Developed through years of rigorous research, this breakthrough heralds a new era of hope, aiming to improve overall quality of life for those affected by schizophrenia with a novel mechanism that's both precise and promising. EuMentis is headquartered in San Diego, CA. For more information, please visit and engage with us on LinkedIn. Media ContactAmy ConradJuniper Pointamy@ Company ContactFrank StonebanksCEOfstonebanks@ View original content to download multimedia: SOURCE EuMentis Therapeutics, Inc. Sign in to access your portfolio
Business Wire
an hour ago
- Business Wire
QualiZeal Welcomes Healthcare Industry Visionary Dr. Aiman Abdel-Malek to Business Advisory Board
DALLAS--(BUSINESS WIRE)--QualiZeal Inc., the world's fastest-growing Quality Engineering (QE) services company, announced the appointment of renowned healthcare industry visionary Dr. Aiman Abdel-Malek to its Business Advisory Board. This strategic move aims to leverage Dr. Abdel-Malek's transformative leadership experience in the healthcare, life sciences, and medical devices sectors as QualiZeal fortifies its position as a leader in the enterprise digital transformation landscape. With more than 25 years in executive leadership roles at GE, Qualcomm, and Insulet Corporation, Dr. Abdel-Malek is a recognized expert in secure, connected diabetes management systems and mobile healthcare solutions. Under his distinguished leadership, Insulet launched the world's first FDA-cleared, smartphone-controlled tubeless insulin patch pump and artificial pancreas. With over 40 patents and publications in secure connected healthcare, digital care delivery, and safe AI, he serves as a board advisor to several companies driving personalized healthcare innovation through digital technology and AI. "Welcoming Dr. Aiman Abdel-Malek to our Business Advisory Board is a tremendous honor," said Kalyan Konda, Co-Founder, Executive Director, and CEO of QualiZeal. "His proven track record in AI-driven healthcare breakthroughs will provide invaluable strategic guidance as we solidify our market leadership and advance toward our goal of quadrupling the company by 2028. Dr. Abdel-Malek's strategic counsel will be crucial in shaping our next generation of innovation, expanding our global impact, and solidifying our position as a leader in modern quality engineering." Dr. Aiman Abdel-Malek shared his enthusiasm about the partnership, stating, 'I believe QualiZeal will redefine how Quality Engineering is being practiced. The highly innovative, patent-pending QMentisAI platform is truly a game-changer. It's the industry's most complete end-to-end GenAI-powered QE platform, dramatically accelerating the journey from functional requirements to automated testing with regulatory-grade precision, reducing process times by over 60%. Backed by visionary leadership and a world-class team, QualiZeal has the clarity, innovation, and momentum to lead the industry. I'm proud to join them on this exciting journey.' About QualiZeal: QualiZeal is the world's fastest-growing Quality Engineering (QE) services company, known for its automation-first, AI-led, and platform-driven approach to software quality. With a diverse portfolio of digital transformation services—including Quality Engineering, Digital Engineering, Advisory & Transformation, and Emerging Technology Testing—QualiZeal empowers leading global organizations to achieve quality excellence and sustainable market leadership. QualiZeal's award-winning proprietary platforms, QMentisAI (patent-pending) and QualiCentral, pioneer the innovative use of AI and GenAI to solve complex QE challenges at speed and scale for clients in their digital transformation journeys. Recognized by Gartner, Everest Group, Forrester, Frost & Sullivan, and NelsonHall, the company has received numerous accolades, including the 2025 Gold Stevie® Award for Fastest Growing Tech Company of the Year (American Business Awards®). Trusted by 70+ global enterprise clients and backed by 850+ elite quality engineers, QualiZeal drives seamless digital transformation—reflected in its industry-leading Net Promoter Score (NPS) of 75. For more information, please visit
Business Wire
an hour ago
- Business Wire
CITEL Reims joins the UL Client Test Data Program: a recognition of the technical expertise and rigor of its laboratory
MIRAMAR, Fla.--(BUSINESS WIRE)-- CITEL, a specialist in surge protection, announces that its testing and research laboratory in Reims has joined the UL Client Test Data Program (CTDP). This participation confirms the site's ability to produce test data that can be used in UL (Underwriters Laboratories) conformity assessment processes, in accordance with UL 1449 5th Edition and CSA-C22.2 No. 269 standards, and in line with quality best practices as described in ISO/IEC 17025. "Participation in the UL Client Test Data Program confirms that our laboratory meets the highest standards of quality and rigor. It is a key lever to improve agility in our developments and better meet our clients' needs." Share This recognition is the result of a thorough audit over several months, conducted by UL's US teams both on-site and remotely. It covered all CITEL's technical resources, personnel expertise, and quality processes. The CITEL Reims laboratory stands out for: A dedicated team of qualified engineers, High-voltage and high-current test equipment enabling a wide range of tests, Rigorous procedures ensuring independence, objectivity, and traceability of results. "Participation in the UL Client Test Data Program confirms that our laboratory meets the highest standards of quality and rigor. It is a key lever to improve agility in our developments and better meet our clients' needs," says Christophe Nicodème, Head of the Reims laboratory. This recognition strengthens CITEL's position as a benchmark player capable of designing, validating, manufacturing, and now certifying its solutions under UL delegation. It also represents a strategic gain in responsiveness, significantly reducing time-to-market for new products. This new milestone reinforces CITEL's commitment to quality and technical expertise. It is part of a broader strategy to strengthen testing laboratories. In fact, CITEL's laboratory in Shanghai is authorized to perform client testing for electrotechnical equipment and component testing under the IECEE system. It has been approved by Dekra at Stage 2 and has also received a nomination certificate to perform tests under the supervision of TUV Rheinland.
